Skip to main content

Table 1 Clinicopathological correlation with H3K18Ac, P300 and SIRT2 expression analyzed by immunohistochemistry

From: Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes

Clinical   H3K18Ac (p) SIRT2 (p) P300 (p)
Extraprostatic Extension No (46) 0.371(0.316–0.434)   0.0152(0.010–0.019)   0.135(0.125–0.150)  
  Yes (24) 0.375(0.308–0.414) 0.71 0.0132(0.011–0.017) 0.17 0.145(0.125–0.162) 0.09
Seminal Vesicle Invasion No (54) 0.373(0.318–0.431)   0.015(0.011–0.019)   0.135(0.125–0.15)  
  Yes (17) 0.365(0.306–0.414) 0.41 0.011(0.010–0.016) 0.12 0.146(0.128–0.165) 0.03
Laterality U/L (4) 0.380(0.323–0.410)   0.010(0.0085–0.013)   0.125(0.118–0.136)  
  B/L (67) 0.371(0.31–0.422) 0.92 0.015(0.011–0.018) 0.16 0.137(0.125–0.153) 0.20
Margins No (44) 0.371(0.312–0.429)   0.0157(0.011–0.019)   0.139(0.126–0.158)  
  Yes (26) 0.373(0.306–0.414) 0.79 0.012(0.010–0.017) 0.07 0.132(0.125–0.147) 0.46
Clinical stage II (42) 0.371(0.316–0.439)   0.015(0.010–0.019)   0.134(0.125–0.150)  
  III (12) 0.358(0.308–0.401)   0.013(0.010–0.017)   0.137(0.126–0.153)  
  IV (16) 0.396(0.311–0.414) 0.64 0.016(0.010–0.018) 0.58 0.146(0.126–0.163 0.13
PSA level (ng/ml) 0–5 (6) 0.343(0.296–0.456)   0.011(0.009–0.015)   0.136(0.124–0.146)  
  5–10 (35) 0.372(0.313–0.414)   0.015(0.012–0.018)   0.133(0.124–0.152)  
  >10 (12) 0.365(0.307–0.425) 0.96 0.011(0.010–0.019) 0.15 0.145(0.134–0.160) 0.51
Gleason score
(3 + 3, 3 + 4) Low/Int (35) 0.371(0.321–0.441)   0.015(0.012–0.019)   0.128(0.121–0.142)  
(4 + 3,4 + 4, 4 + 5) High (19) 0.345(0.298–0.412) 0.15 0.011(0.009–0.015) 0.02 0.134(0.124–0.152) 0.68
  1. Relative staining intensity of H3K18Ac, SIRT2 and P300 (mean, standard deviation expressed in 0D units) compared to clinicopathological correlates